Scalper1 News
Biotech Bluebird Bio (BLUE) jumped to a new high above 186 early Thursday after it released preliminary data on its gene therapy for two blood diseases. Bluebird issued highlights of its presentation next month at the Congress of the European Hematology Association in Vienna, describing interim data from its phase one/two study of its drug LentiGlobin in beta thalassemia sickle-cell disease. Both are genetic diseases causing severe anemia and Scalper1 News
Scalper1 News